Maryland Heights, MO, February 18, 2017 --(PR.com
)-- The global erectile dysfunction (ED) drugs market is estimated to reach nearly USD 4.2 Billion in 2020, due to common age-related health conditions and lifestyle changes worldwide.
Browse Erectile Dysfunction Drugs Market by Drug Type (Brand) – Cialis (Tadalafil), Helleva (Lodenafil Carbonate), Levitra/Staxyn (Vardenafil), MUSE (Medicated Urethral System for Erection), Mvix (Mirodenafil), Stendra/Spedra (Avanafil), Viagra (Sildenafil Citrate), Zydena (Udenafil) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs – Uprima (Apomorphine), Vitaros (Alprostadil) 2016-2020 at https://www.ihealthcareanalyst.com/report/erectile-dysfunction-drugs-market/
Diseases, nutritional status, trauma, surgical procedures, or medications can affect erectile function by altering the nervous, vascular, or hormonal systems. Aging is considered as the major factor responsible for impeding the normal function of erection, while other factors include cardiovascular diseases, diabetes mellitus, spinal cord injuries, hypertension, and medications. The major types of erectile dysfunction include psychological erectile dysfunction, priapism characterized by painful erection in the absence of sexual stimulation, and Peyronie’s disease. Phosphodiesterase-5 (PDE-5) inhibitors are one of the most widely used and effective types of medication for treating erectile dysfunction. The first line of treatment for ED comprises oral medication of PDE 5 inhibitors, namely, sildenafil citrate, tadalafil, vardenafil, udenafil and others.
The global erectile dysfunction (ED) drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type by major brands such as Cialis (tadalafil), Helleva (lodenafil carbonate), Levitra/Staxyn (vardenafil), MUSE (Medicated Urethral System for Erection), Mvix (mirodenafil), Stendra/Spedra (avanafil), Viagra (sildenafil citrate), Zydena (udenafil), etc. and clinical pipeline analysis of phase 1, 2 and 3 drugs such as Uprima (apomorphine), Vitaros (alprostadil), and forecasts growth trends (CAGR% - 2016 to 2020). The global erectile dysfunction drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global erectile dysfunction drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global erectile dysfunction drugs market and included in this report are Pfizer, Inc., Eli Lilly and Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd., and Vivus, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/erectile-dysfunction-drugs-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043